|
UNITED STATES Washington, D.C. 20549 |
OMB APPROVAL |
|
OMB Number: 3235-0582 | |
|
Expires: March 31, 2021 | |
|
Estimated average burden | |
|
hours per response........7.2 |
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811- 04889
Tekla Healthcare Investors
(Exact name of registrant as specified in charter)
100 Federal Street, 19th Floor, Boston, MA |
|
02110 |
(Address of principal executive offices) |
|
(Zip code) |
Laura Woodward
Tekla Healthcare Investors
100 Federal Street, 19th Floor, Boston MA 02110
(Name and address of agent for service)
Registrants telephone number, including area code: 617-772-8500
Date of fiscal year end: September 30
Date of reporting period: 7/1/17-6/30/18
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrants proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.
Item 1. Proxy Voting Record.
Vote Summary
ABBOTT LABORATORIES
Security |
002824100 |
Meeting Type |
Annual |
Ticker Symbol |
ABT |
Meeting Date |
27-Apr-2018 |
Record Date |
28-Feb-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
R.J. Alpern |
|
|
|
For |
|
For |
|
|
|
2 |
R.S. Austin |
|
|
|
For |
|
For |
|
|
|
3 |
S.E. Blount |
|
|
|
For |
|
For |
|
|
|
4 |
E.M. Liddy |
|
|
|
For |
|
For |
|
|
|
5 |
N. McKinstry |
|
|
|
For |
|
For |
|
|
|
6 |
P.N. Novakovic |
|
|
|
For |
|
For |
|
|
|
7 |
W.A. Osborn |
|
|
|
For |
|
For |
|
|
|
8 |
S.C. Scott III |
|
|
|
For |
|
For |
|
|
|
9 |
D.J. Starks |
|
|
|
For |
|
For |
|
|
|
10 |
J.G. Stratton |
|
|
|
For |
|
For |
|
|
|
11 |
G.F. Tilton |
|
|
|
For |
|
For |
|
|
|
12 |
M.D. White |
|
|
|
For |
|
For |
|
2. |
|
Ratification of Ernst & Young LLP as Auditors |
|
Management |
|
For |
|
For |
| |
3. |
|
Say on Pay - An Advisory Vote to Approve Executive Compensation |
|
Management |
|
For |
|
For |
| |
4. |
|
Shareholder Proposal - Independent Board Chairman |
|
Shareholder |
|
For |
|
Against |
|
ABBVIE INC.
Security |
00287Y109 |
Meeting Type |
Annual |
Ticker Symbol |
ABBV |
Meeting Date |
04-May-2018 |
Record Date |
07-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Roxanne S. Austin |
|
|
|
For |
|
For |
|
|
|
2 |
Richard A. Gonzalez |
|
|
|
For |
|
For |
|
|
|
3 |
Rebecca B. Roberts |
|
|
|
For |
|
For |
|
|
|
4 |
Glenn F. Tilton |
|
|
|
For |
|
For |
|
2. |
|
Ratification of Ernst & Young LLP as AbbVies independent registered public accounting firm for 2018 |
|
Management |
|
For |
|
For |
| |
3. |
|
Say on Pay - An advisory vote on the approval of executive compensation |
|
Management |
|
For |
|
For |
| |
4. |
|
Say When on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation |
|
Management |
|
1 Year |
|
For |
| |
5. |
|
Approval of a management proposal regarding amendment of the certificate of incorporation for the annual election of directors |
|
Management |
|
For |
|
For |
| |
6. |
|
Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting |
|
Management |
|
For |
|
For |
| |
7. |
|
Stockholder Proposal - to Issue an Annual Report on Lobbying |
|
Shareholder |
|
Against |
|
For |
| |
8. |
|
Stockholder Proposal - to Separate Chair and CEO |
|
Shareholder |
|
For |
|
Against |
| |
9. |
|
Stockholder Proposal - to Issue an Annual Compensation Committee Report on Drug Pricing |
|
Shareholder |
|
Against |
|
For |
|
AC IMMUNE SA
Security |
H00263105 |
Meeting Type |
Special |
Ticker Symbol |
ACIU |
Meeting Date |
27-Apr-2018 |
Record Date |
13-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors |
|
Management |
|
For |
|
N/A |
|
2.A |
|
Election of Douglas Williams as Member to the Board of Directors |
|
Management |
|
For |
|
N/A |
|
2.B |
|
Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee |
|
Management |
|
For |
|
N/A |
|
3.a |
|
Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018 |
|
Management |
|
For |
|
N/A |
|
3.b |
|
Vote on Equity for the new Member of the Board of Directors |
|
Management |
|
For |
|
N/A |
|
4.a |
|
Share Capital Increase for Institutional Investors |
|
Management |
|
For |
|
N/A |
|
4.b |
|
Share Capital Increase for Current Shareholders |
|
Management |
|
For |
|
N/A |
|
AC IMMUNE SA
Security |
H00263105 |
Meeting Type |
Annual |
Ticker Symbol |
ACIU |
Meeting Date |
06-Jul-2018 |
Record Date |
23-May-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
A. |
|
In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors |
|
Management |
|
For |
|
N/A |
|
1. |
|
Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017 |
|
Management |
|
For |
|
N/A |
|
2. |
|
Appropriation of Loss |
|
Management |
|
For |
|
N/A |
|
3. |
|
Discharge of the Members of the Board of Directors and the Executive Committee |
|
Management |
|
For |
|
N/A |
|
4a. |
|
Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019 |
|
Management |
|
For |
|
N/A |
|
4b. |
|
Vote on Equity for Members of the Board of Directors |
|
Management |
|
For |
|
N/A |
|
4c. |
|
Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019 |
|
Management |
|
For |
|
N/A |
|
4d. |
|
Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018 |
|
Management |
|
For |
|
N/A |
|
4e. |
|
Vote on Equity for Members of the Executive Committee |
|
Management |
|
For |
|
N/A |
|
5a. |
|
Re-election of Martin Velasco as member and Chairman of the Board of Directors |
|
Management |
|
For |
|
N/A |
|
5b. |
|
Re-election of Peter Bollmann as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
5c. |
|
Re-election of Friedrich von Bohlen as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
5d. |
|
Re-election of Andrea Pfeifer as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
5e. |
|
Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit |
|
Management |
|
For |
|
N/A |
|
5f. |
|
Re-election of Tom Graney as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
5g. |
|
Re-election of Douglas Williams as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
5h. |
|
Election of Werner Lanthaler as the Member of the Board |
|
Management |
|
For |
|
N/A |
|
6a. |
|
Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee |
|
Management |
|
For |
|
N/A |
|
6b. |
|
Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee |
|
Management |
|
For |
|
N/A |
|
6c. |
|
Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee |
|
Management |
|
For |
|
N/A |
|
7. |
|
Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva |
|
Management |
|
For |
|
N/A |
|
8. |
|
Election of the Auditors, PricewaterhouseCoopers SA, Pully |
|
Management |
|
For |
|
N/A |
|
9a. |
|
Share Capital Increase for Institutional Investors |
|
Management |
|
For |
|
N/A |
|
9b. |
|
Share Capital Increase for Current Shareholders |
|
Management |
|
For |
|
N/A |
|
ACADIA HEALTHCARE COMPANY, INC.
Security |
00404A109 |
Meeting Type |
Annual |
Ticker Symbol |
ACHC |
Meeting Date |
03-May-2018 |
Record Date |
09-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1.1 |
|
Election of Director: E. Perot Bissell |
|
Management |
|
For |
|
For |
|
1.2 |
|
Election of Director: Vicky B. Gregg |
|
Management |
|
For |
|
For |
|
2. |
|
Advisory vote on the compensation of the Companys named executive officers as presented in the Proxy Statement. |
|
Management |
|
For |
|
For |
|
3. |
|
Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ACADIA PHARMACEUTICALS INC.
Security |
004225108 |
Meeting Type |
Annual |
Ticker Symbol |
ACAD |
Meeting Date |
06-Jun-2018 |
Record Date |
13-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Julian Baker |
|
|
|
For |
|
For |
|
|
|
2 |
Stephen Biggar, M.D PhD |
|
|
|
For |
|
For |
|
|
|
3 |
Daniel Soland |
|
|
|
For |
|
For |
|
2. |
|
To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares. |
|
Management |
|
For |
|
For |
| |
3. |
|
To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting. |
|
Management |
|
For |
|
For |
| |
4. |
|
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ACCELERON PHARMA INC.
Security |
00434H108 |
Meeting Type |
Annual |
Ticker Symbol |
XLRN |
Meeting Date |
06-Jun-2018 |
Record Date |
09-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Class II Director: Habib J. Dable |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Class II Director: Terrence C. Kearney |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Class II Director: Karen L. Smith, M.D., Ph.D. |
|
Management |
|
For |
|
For |
|
2. |
|
To approve, on an advisory basis, the compensation paid to the Companys named executive officers as disclosed in the proxy statement. |
|
Management |
|
For |
|
For |
|
3. |
|
To ratify the selection of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
AKEBIA THERAPEUTICS, INC.
Security |
00972D105 |
Meeting Type |
Annual |
Ticker Symbol |
AKBA |
Meeting Date |
14-Jun-2018 |
Record Date |
20-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Michael D. Clayman |
|
|
|
For |
|
For |
|
|
|
2 |
Duane Nash |
|
|
|
For |
|
For |
|
|
|
3 |
Ronald C. Renaud, Jr. |
|
|
|
For |
|
For |
|
|
|
4 |
John P. Butler |
|
|
|
For |
|
For |
|
|
|
5 |
Muneer A. Satter |
|
|
|
For |
|
For |
|
|
|
6 |
Michael S. Wyzga |
|
|
|
For |
|
For |
|
2. |
|
Ratification of the appointment of Ernst & Young LLP as the companys independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ALBIREO PHARMA INC.
Security |
01345P106 |
Meeting Type |
Annual |
Ticker Symbol |
ALBO |
Meeting Date |
08-Jun-2018 |
Record Date |
18-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Ronald H.W. Cooper |
|
|
|
For |
|
For |
|
|
|
2 |
Anne Klibanski, M.D. |
|
|
|
For |
|
For |
|
|
|
3 |
Stephanie S. Okey, M.S. |
|
|
|
For |
|
For |
|
2. |
|
To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan. |
|
Management |
|
For |
|
For |
| |
3. |
|
To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan. |
|
Management |
|
For |
|
For |
| |
4. |
|
To ratify the appointment of Ernst & Young LLP as Albireos independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ALDER BIOPHARMACEUTICALS, INC.
Security |
014339105 |
Meeting Type |
Annual |
Ticker Symbol |
ALDR |
Meeting Date |
23-May-2018 |
Record Date |
20-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Paul B. Cleveland |
|
|
|
For |
|
For |
|
|
|
2 |
Stephen M. Dow |
|
|
|
For |
|
For |
|
|
|
3 |
A. Bruce Montgomery |
|
|
|
For |
|
For |
|
2. |
|
To approve, on an advisory basis, the compensation of the Companys named executive officers, as disclosed in the accompanying proxy statement. |
|
Management |
|
For |
|
For |
| |
3. |
|
To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ALEXION PHARMACEUTICALS, INC.
Security |
015351109 |
Meeting Type |
Annual |
Ticker Symbol |
ALXN |
Meeting Date |
08-May-2018 |
Record Date |
12-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Felix J. Baker |
|
|
|
For |
|
For |
|
|
|
2 |
David R. Brennan |
|
|
|
For |
|
For |
|
|
|
3 |
Christopher J. Coughlin |
|
|
|
For |
|
For |
|
|
|
4 |
Deborah Dunsire |
|
|
|
For |
|
For |
|
|
|
5 |
Paul A. Friedman |
|
|
|
For |
|
For |
|
|
|
6 |
Ludwig N. Hantson |
|
|
|
For |
|
For |
|
|
|
7 |
John T. Mollen |
|
|
|
For |
|
For |
|
|
|
8 |
Francois Nader |
|
|
|
For |
|
For |
|
|
|
9 |
Judith A. Reinsdorf |
|
|
|
For |
|
For |
|
|
|
10 |
Andreas Rummelt |
|
|
|
For |
|
For |
|
2. |
|
Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm. |
|
Management |
|
For |
|
For |
| |
3. |
|
Approval of a non-binding advisory vote of the 2017 compensation paid to Alexions named executive officers. |
|
Management |
|
For |
|
For |
| |
4. |
|
To request the Board to require an independent Chairman. |
|
Shareholder |
|
For |
|
Against |
|
ALKERMES PLC
Security |
G01767105 |
Meeting Type |
Annual |
Ticker Symbol |
ALKS |
Meeting Date |
23-May-2018 |
Record Date |
23-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Director: Floyd E. Bloom, M.D. |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Director: Nancy L. Snyderman, M.D. |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Director: Nancy Wysenski |
|
Management |
|
For |
|
For |
|
2. |
|
To approve, on an advisory basis, the compensation of the Companys named executive officers. |
|
Management |
|
For |
|
For |
|
3. |
|
To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Companys named executive officers. |
|
Management |
|
1 Year |
|
For |
|
4. |
|
To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firms remuneration. |
|
Management |
|
For |
|
For |
|
5. |
|
To approve the Alkermes plc 2018 Stock Option and Incentive plan. |
|
Management |
|
For |
|
For |
|
ALLERGAN PLC
Security |
G0177J108 |
Meeting Type |
Annual |
Ticker Symbol |
AGN |
Meeting Date |
02-May-2018 |
Record Date |
06-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Director: Nesli Basgoz, M.D. |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Director: Paul M. Bisaro |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Director: Joseph H. Boccuzi |
|
Management |
|
For |
|
For |
|
1d. |
|
Election of Director: Christopher W. Bodine |
|
Management |
|
For |
|
For |
|
1e. |
|
Election of Director: Adriane M. Brown |
|
Management |
|
For |
|
For |
|
1f. |
|
Election of Director: Christopher J. Coughlin |
|
Management |
|
For |
|
For |
|
1g. |
|
Election of Director: Carol Anthony (John) Davidson |
|
Management |
|
For |
|
For |
|
1h. |
|
Election of Director: Catherine M. Klema |
|
Management |
|
For |
|
For |
|
1i. |
|
Election of Director: Peter J. McDonnell, M.D. |
|
Management |
|
For |
|
For |
|
1j. |
|
Election of Director: Patrick J. OSullivan |
|
Management |
|
For |
|
For |
|
1k. |
|
Election of Director: Brenton L. Saunders |
|
Management |
|
For |
|
For |
|
1l. |
|
Election of Director: Fred G. Weiss |
|
Management |
|
For |
|
For |
|
2. |
|
To approve, in a non-binding vote, Named Executive Officer compensation. |
|
Management |
|
For |
|
For |
|
3. |
|
To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Companys independent auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLPs remuneration. |
|
Management |
|
For |
|
For |
|
4. |
|
To renew the authority of the directors of the Company (the Directors) to issue shares. |
|
Management |
|
For |
|
For |
|
5A. |
|
To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders. |
|
Management |
|
For |
|
For |
|
5B. |
|
To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment. |
|
Management |
|
For |
|
For |
|
6. |
|
To consider a shareholder proposal requiring an independent Board Chairman, if properly presented at the meeting. |
|
Shareholder |
|
Against |
|
For |
|
ALLIQUA BIOMEDICAL, INC.
Security |
019621200 |
Meeting Type |
Special |
Ticker Symbol |
ALQA |
Meeting Date |
13-Sep-2017 |
Record Date |
26-Jul-2017 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
TO RATIFY THE FILING AND EFFECTIVENESS OF THE CERTIFICATE OF AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON MAY 6, 2016 AND THE INCREASE IN THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK EFFECTED THEREBY. |
|
Management |
|
For |
|
For |
|
2. |
|
TO APPROVE THE PROPOSAL TO AUTHORIZE THE COMPANYS BOARD OF DIRECTORS, IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANYS STOCKHOLDERS IN 2018, TO AMEND THE COMPANYS CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANYS COMMON STOCK, AT A RATIO IN THE RANGE OF ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL). |
|
Management |
|
For |
|
For |
|
3. |
|
TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ANY OF THE FOREGOING PROPOSALS. |
|
Management |
|
For |
|
For |
|
ALLIQUA BIOMEDICAL, INC.
Security |
019621309 |
Meeting Type |
Special |
Ticker Symbol |
ALQA |
Meeting Date |
27-Apr-2018 |
Record Date |
23-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement (the Asset Sale Proposal). |
|
Management |
|
For |
|
For |
|
2. |
|
A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Companys named executive officers in connection with the asset sale (the Advisory Proposal). |
|
Management |
|
For |
|
For |
|
3. |
|
A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal (the Adjournment Proposal). |
|
Management |
|
For |
|
For |
|
ALLIQUA BIOMEDICAL, INC.
Security |
019621309 |
Meeting Type |
Annual |
Ticker Symbol |
ALQA |
Meeting Date |
26-Jun-2018 |
Record Date |
03-May-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
David Johnson |
|
|
|
For |
|
For |
|
|
|
2 |
Joseph Leone |
|
|
|
For |
|
For |
|
|
|
3 |
Gary Restani |
|
|
|
For |
|
For |
|
|
|
4 |
Jeffrey Sklar |
|
|
|
For |
|
For |
|
|
|
5 |
Mark Wagner |
|
|
|
For |
|
For |
|
2. |
|
Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ALNYLAM PHARMACEUTICALS, INC.
Security |
02043Q107 |
Meeting Type |
Annual |
Ticker Symbol |
ALNY |
Meeting Date |
10-May-2018 |
Record Date |
15-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Class II Director: Dennis A. Ausiello, M.D. |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Class II Director: John K. Clarke |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Class II Director: Marsha H. Fanucci |
|
Management |
|
For |
|
For |
|
1d. |
|
Election of Class II Director: David E.I. Pyott |
|
Management |
|
For |
|
For |
|
2. |
|
To approve the 2018 Stock Incentive Plan. |
|
Management |
|
For |
|
For |
|
3. |
|
To approve, in a non-binding advisory vote, the compensation of Alnylams named executive officers. |
|
Management |
|
For |
|
For |
|
4. |
|
To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylams independent auditors for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
AMARIN CORPORATION PLC
Security |
023111206 |
Meeting Type |
Annual |
Ticker Symbol |
AMRN |
Meeting Date |
14-May-2018 |
Record Date |
18-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
To re-elect Mr. John F. Thero as a director. |
|
Management |
|
For |
|
For |
|
2. |
|
To re-elect Mr. Patrick J. OSullivan as a director. |
|
Management |
|
For |
|
For |
|
3. |
|
To hold an advisory (non-binding) vote to approve the compensation of the Companys named executive officers as described in full in the accompanying Proxy Statement. |
|
Management |
|
For |
|
For |
|
4. |
|
To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement. |
|
Management |
|
For |
|
For |
|
AMGEN INC.
Security |
031162100 |
Meeting Type |
Annual |
Ticker Symbol |
AMGN |
Meeting Date |
22-May-2018 |
Record Date |
23-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Director: Dr. Wanda M. Austin |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Director: Mr. Robert A. Bradway |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Director: Dr. Brian J. Druker |
|
Management |
|
For |
|
For |
|
1d. |
|
Election of Director: Mr. Robert A. Eckert |
|
Management |
|
For |
|
For |
|
1e. |
|
Election of Director: Mr. Greg C. Garland |
|
Management |
|
For |
|
For |
|
1f. |
|
Election of Director: Mr. Fred Hassan |
|
Management |
|
For |
|
For |
|
1g. |
|
Election of Director: Dr. Rebecca M. Henderson |
|
Management |
|
For |
|
For |
|
1h. |
|
Election of Director: Mr. Frank C. Herringer |
|
Management |
|
For |
|
For |
|
1i. |
|
Election of Director: Mr. Charles M. Holley, Jr. |
|
Management |
|
For |
|
For |
|
1j. |
|
Election of Director: Dr. Tyler Jacks |
|
Management |
|
For |
|
For |
|
1k. |
|
Election of Director: Ms. Ellen J. Kullman |
|
Management |
|
For |
|
For |
|
1l. |
|
Election of Director: Dr. Ronald D. Sugar |
|
Management |
|
For |
|
For |
|
1m. |
|
Election of Director: Dr. R. Sanders Williams |
|
Management |
|
For |
|
For |
|
2. |
|
Advisory vote to approve our executive compensation. |
|
Management |
|
For |
|
For |
|
3. |
|
To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
4. |
|
Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation. |
|
Shareholder |
|
Against |
|
For |
|
AMICUS THERAPEUTICS, INC.
Security |
03152W109 |
Meeting Type |
Annual |
Ticker Symbol |
FOLD |
Meeting Date |
07-Jun-2018 |
Record Date |
16-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Donald J. Hayden, Jr. |
|
|
|
For |
|
For |
|
|
|
2 |
Craig Wheeler |
|
|
|
For |
|
For |
|
2. |
|
Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000 |
|
Management |
|
For |
|
For |
| |
3. |
|
Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool |
|
Management |
|
For |
|
For |
| |
4. |
|
Ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018 |
|
Management |
|
For |
|
For |
| |
5. |
|
Approval, on an advisory basis, the Companys executive compensation |
|
Management |
|
For |
|
For |
|
AMPHIVENA THERAPEUTICS, INC
Security |
N/A |
Meeting Type |
Written Consent |
Ticker Symbol |
N/A |
Meeting Date |
20-Dec-2017 |
Record Date |
N/A |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Approval of Amended and Restated Certificate of Incorporation |
|
Management |
|
For |
|
For |
|
2. |
|
Approval of Bridge Loan and Waiver of Right of First Offer |
|
Management |
|
For |
|
For |
|
3. |
|
Omnibus Resolutions |
|
Management |
|
For |
|
For |
|
ANTHEM, INC.
Security |
036752103 |
Meeting Type |
Annual |
Ticker Symbol |
ANTM |
Meeting Date |
16-May-2018 |
Record Date |
09-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Director: Lewis Hay, III |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Director: Julie A. Hill |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Director: Antonio F. Neri |
|
Management |
|
For |
|
For |
|
1d. |
|
Election of Director: Ramiro G. Peru |
|
Management |
|
For |
|
For |
|
2. |
|
To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2018. |
|
Management |
|
For |
|
For |
|
3. |
|
Advisory vote to approve the compensation of our named executive officers. |
|
Management |
|
For |
|
For |
|
4. |
|
To approve proposed amendments to our Articles of Incorporation to allow shareholders owning 20% or more of our common stock to call special meetings of shareholders. |
|
Management |
|
For |
|
For |
|
5. |
|
Shareholder proposal to allow shareholders owning 10% or more of our common stock to call special meetings of shareholders. |
|
Shareholder |
|
Against |
|
For |
|
ARENA PHARMACEUTICALS, INC.
Security |
040047607 |
Meeting Type |
Annual |
Ticker Symbol |
ARNA |
Meeting Date |
13-Jun-2018 |
Record Date |
24-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Jayson Dallas, M.D. |
|
|
|
For |
|
For |
|
|
|
2 |
Oliver Fetzer, Ph.D. |
|
|
|
For |
|
For |
|
|
|
3 |
Jennifer Jarrett |
|
|
|
For |
|
For |
|
|
|
4 |
Amit D. Munshi |
|
|
|
For |
|
For |
|
|
|
5 |
Garry A. Neil, M.D. |
|
|
|
For |
|
For |
|
|
|
6 |
Tina S. Nova, Ph.D. |
|
|
|
For |
|
For |
|
|
|
7 |
Randall E. Woods |
|
|
|
For |
|
For |
|
2. |
|
To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice. |
|
Management |
|
For |
|
For |
| |
3. |
|
To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan. |
|
Management |
|
For |
|
For |
| |
4. |
|
To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
ASCENDIS PHARMA A S
Security |
04351P101 |
Meeting Type |
Annual |
Ticker Symbol |
ASND |
Meeting Date |
29-May-2018 |
Record Date |
19-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Election of Chairman of the Meeting |
|
Management |
|
For |
|
For |
|
2. |
|
Report on the Companys Activities during the Past Year |
|
Management |
|
For |
|
For |
|
3. |
|
Presentation of Audited Annual Report with Auditors Statement for Approval and Discharge of the Board of Directors and Management |
|
Management |
|
For |
|
For |
|
4. |
|
Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report |
|
Management |
|
For |
|
For |
|
5a. |
|
Election of Board Member: Albert Cha (Class II) |
|
Management |
|
For |
|
For |
|
5b. |
|
Election of Board Member: Birgitte Volck (Class II) |
|
Management |
|
For |
|
For |
|
5c. |
|
Election of Board Member: Martin Olin (Class II) |
|
Management |
|
For |
|
For |
|
6. |
|
Election of State-authorized Public Auditor |
|
Management |
|
For |
|
For |
|
7. |
|
Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information. |
|
Management |
|
For |
|
For |
|
AURIS MEDICAL HOLDING AG
Security |
H03579101 |
Meeting Type |
Annual |
Ticker Symbol |
EARS |
Meeting Date |
12-Mar-2018 |
Record Date |
09-Feb-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ...(due to space limits, see proxy statement for full proposal). |
|
Management |
|
For |
|
For |
|
2. |
|
Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Companys Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschaftsfuhrung der Gesellschaft betrauten Personen. |
|
Management |
|
For |
|
For |
|
3.1 |
|
Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergutung des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
3.2 |
|
Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergutung der Geschaftsleitung fur das Geschaftsjahr 2019. |
|
Management |
|
For |
|
For |
|
4.1 |
|
Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Prasident des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
4.2 |
|
Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
4.3 |
|
Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
4.4 |
|
Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
4.5 |
|
Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats. |
|
Management |
|
For |
|
For |
|
5.1 |
|
Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergutungsausschusses. |
|
Management |
|
For |
|
For |
|
5.2 |
|
Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergutungsausschusses. |
|
Management |
|
For |
|
For |
|
6. |
|
Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle. |
|
Management |
|
For |
|
For |
|
7. |
|
Re-election of the Independent Proxy. German Version: Wiederwahl des unabhangigen Stimmrechtsvertreters. |
|
Management |
|
For |
|
For |
|
8. |
|
General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekundigten Antragen / Verhandlungsgegenstanden. |
|
Management |
|
For |
|
For |
|
BEIGENE LTD
Security |
07725L102 |
Meeting Type |
Annual |
Ticker Symbol |
BGNE |
Meeting Date |
06-Jun-2018 |
Record Date |
20-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ...(due to space limits, see proxy material for full proposal). |
|
Management |
|
For |
|
For |
|
2. |
|
THAT Michael Goller be and is hereby re-elected to serve as a ...(due to space limits, see proxy material for full proposal). |
|
Management |
|
For |
|
For |
|
3. |
|
THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. |
|
Management |
|
For |
|
For |
|
4. |
|
THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted. |
|
Management |
|
For |
|
For |
|
5. |
|
THAT the appointment of Ernst & Young Hua Ming LLP as the Companys independent registered public accounting firm for the ...(due to space limits, see proxy material for full proposal). |
|
Management |
|
For |
|
For |
|
6. |
|
THAT, on a non-binding, advisory basis, the compensation of the Companys named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved. |
|
Management |
|
For |
|
For |
|
7. |
|
THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Companys named executive officers will be held at the frequency hereby approved. |
|
Management |
|
1 Year |
|
For |
|
BIOCLIN THERAPEUTICS, INC.
Security |
N/A |
Meeting Type |
Written Consent |
Ticker Symbol |
N/A |
Meeting Date |
27-Sep-2017 |
Record Date |
N/A |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Election of Director |
|
Management |
|
For |
|
For |
|
2. |
|
General Authorizing Resolution |
|
Management |
|
For |
|
For |
|
BIOCLIN THERAPEUTICS, INC.
Security |
N/A |
Meeting Type |
Written Consent |
Ticker Symbol |
N/A |
Meeting Date |
24-Apr-2018 |
Record Date |
N/A |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Amendment and Restatement of Restated Certificate of Incorporation |
|
Management |
|
For |
|
For |
|
2. |
|
Series B Preferred Stock Financing |
|
Management |
|
For |
|
For |
|
3. |
|
Waiver of Preemptive Rights |
|
Management |
|
For |
|
For |
|
4. |
|
Notice of Interested Party Transactions |
|
Management |
|
For |
|
For |
|
5. |
|
Amendment of 2013 Stock and Option Grant Plan |
|
Management |
|
For |
|
For |
|
6. |
|
General Authorizing Resolution |
|
Management |
|
For |
|
For |
|
BIOCLIN THERAPEUTICS, INC.
Security |
N/A |
Meeting Type |
Written Consent |
Ticker Symbol |
N/A |
Meeting Date |
21-May-2018 |
Record Date |
N/A |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1. |
|
Election of Director |
|
Management |
|
For |
|
For |
|
2. |
|
General Authorizing Resolution |
|
Management |
|
For |
|
For |
|
BIOGEN INC.
Security |
09062X103 |
Meeting Type |
Annual |
Ticker Symbol |
BIIB |
Meeting Date |
12-Jun-2018 |
Record Date |
17-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Director: Alexander J. Denner |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Director: Caroline D. Dorsa |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Director: Nancy L. Leaming |
|
Management |
|
For |
|
For |
|
1d. |
|
Election of Director: Richard C. Mulligan |
|
Management |
|
For |
|
For |
|
1e. |
|
Election of Director: Robert W. Pangia |
|
Management |
|
For |
|
For |
|
1f. |
|
Election of Director: Stelios Papadopoulos |
|
Management |
|
For |
|
For |
|
1g. |
|
Election of Director: Brian S. Posner |
|
Management |
|
For |
|
For |
|
1h. |
|
Election of Director: Eric K. Rowinsky |
|
Management |
|
For |
|
For |
|
1i. |
|
Election of Director: Lynn Schenk |
|
Management |
|
For |
|
For |
|
1j. |
|
Election of Director: Stephen A. Sherwin |
|
Management |
|
For |
|
For |
|
1k. |
|
Election of Director: Michel Vounatsos |
|
Management |
|
For |
|
For |
|
2. |
|
To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.s independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
3. |
|
Say on Pay - To approve an advisory vote on executive compensation. |
|
Management |
|
For |
|
For |
|
4. |
|
Stockholder proposal requesting certain proxy access bylaw amendments. |
|
Shareholder |
|
Against |
|
For |
|
5. |
|
Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements. |
|
Shareholder |
|
Against |
|
For |
|
BIOHAVEN PHARMACEUTICAL HLDG CO LTD
Security |
G11196105 |
Meeting Type |
Annual |
Ticker Symbol |
BHVN |
Meeting Date |
01-May-2018 |
Record Date |
26-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1A. |
|
Election of Director: Dr. Eric I. Aguiar |
|
Management |
|
For |
|
For |
|
1B. |
|
Election of Director: Dr. Albert Cha |
|
Management |
|
For |
|
For |
|
1C. |
|
Election of Director: Ms. Julia P. Gregory |
|
Management |
|
For |
|
For |
|
2. |
|
Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018. |
|
Management |
|
For |
|
For |
|
BIOMARIN PHARMACEUTICAL INC.
Security |
09061G101 |
Meeting Type |
Annual |
Ticker Symbol |
BMRN |
Meeting Date |
05-Jun-2018 |
Record Date |
09-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Jean-Jacques Bienaime |
|
|
|
For |
|
For |
|
|
|
2 |
Willard Dere |
|
|
|
For |
|
For |
|
|
|
3 |
Michael Grey |
|
|
|
For |
|
For |
|
|
|
4 |
Elaine J. Heron |
|
|
|
For |
|
For |
|
|
|
5 |
Robert J. Hombach |
|
|
|
For |
|
For |
|
|
|
6 |
V. Bryan Lawlis |
|
|
|
For |
|
For |
|
|
|
7 |
Alan J. Lewis |
|
|
|
For |
|
For |
|
|
|
8 |
Richard A. Meier |
|
|
|
For |
|
For |
|
|
|
9 |
David E.I. Pyott |
|
|
|
For |
|
For |
|
|
|
10 |
Dennis J. Slamon |
|
|
|
For |
|
For |
|
2. |
|
To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
| |
3. |
|
To approve, on an advisory basis, the compensation of the Companys Named Executive Officers as disclosed in the Proxy Statement. |
|
Management |
|
For |
|
For |
|
BLUEBIRD BIO, INC.
Security |
09609G100 |
Meeting Type |
Annual |
Ticker Symbol |
BLUE |
Meeting Date |
20-Jun-2018 |
Record Date |
23-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1a. |
|
Election of Class II Director: John O. Agwunobi, M.D. |
|
Management |
|
For |
|
For |
|
1b. |
|
Election of Class II Director: Mary Lynne Hedley, Ph.D |
|
Management |
|
For |
|
For |
|
1c. |
|
Election of Class II Director: Daniel S. Lynch |
|
Management |
|
For |
|
For |
|
2. |
|
To hold a non-binding advisory vote on the compensation paid to the Companys named executive officers. |
|
Management |
|
For |
|
For |
|
3. |
|
To ratify the appointment of Ernst & Young LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. |
|
Management |
|
For |
|
For |
|
BLUEPRINT MEDICINES CORPORATION
Security |
09627Y109 |
Meeting Type |
Annual |
Ticker Symbol |
BPMC |
Meeting Date |
20-Jun-2018 |
Record Date |
23-Apr-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
| |
1. |
|
DIRECTOR |
|
Management |
|
|
|
|
| |
|
|
1 |
Daniel S. Lynch |
|
|
|
For |
|
For |
|
|
|
2 |
George D. Demetri, M.D. |
|
|
|
For |
|
For |
|
|
|
3 |
Lynn Seely, M.D. |
|
|
|
For |
|
For |
|
2. |
|
To approve an advisory vote on named executive officer compensation. |
|
Management |
|
For |
|
For |
| |
3. |
|
To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation. |
|
Management |
|
1 Year |
|
For |
| |
4. |
|
Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018. |
|
Management |
|
For |
|
For |
|
BRISTOL-MYERS SQUIBB COMPANY
Security |
110122108 |
Meeting Type |
Annual |
Ticker Symbol |
BMY |
Meeting Date |
01-May-2018 |
Record Date |
14-Mar-2018 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1A. |
|
Election of Director: P. J. Arduini |
|
Management |
|
For |
|
For |
|
1B. |
|
Election of Director: J. Baselga, M.D., Ph.D. |
|
Management |
|
For |
|
For |
|
1C. |
|
Election of Director: R. J. Bertolini |
|
Management |
|
For |
|
For |
|
1D. |
|
Election of Director: G. Caforio, M.D. |
|
Management |
|
For |
|
For |
|
1E. |
|
Election of Director: M. W. Emmens |
|
Management |
|
For |
|
For |
|
1F. |
|
Election of Director: M. Grobstein |
|
Management |
|
For |
|
For |
|
1G. |
|
Election of Director: A. J. Lacy |
|
Management |
|
For |
|
For |
|
1H. |
|
Election of Director: D. C. Paliwal |
|
Management |
|
For |
|
For |
|
1I. |
|
Election of Director: T. R. Samuels |
|
Management |
|
For |
|
For |
|
1J. |
|
Election of Director: G. L. Storch |
|
Management |
|
For |
|
For |
|
1K. |
|
Election of Director: V. L. Sato, Ph.D. |
|
Management |
|
For |
|
For |
|
1L. |
|
Election of Director: K. H. Vousden, Ph.D. |
|
Management |
|
For |
|
For |
|
2. |
|
Advisory vote to approve the compensation of our Named Executive Officers |
|
Management |
|
For |
|
For |
|
3. |
|
Ratification of the appointment of an independent registered public accounting firm |
|
Management |
|
For |
|
For |
|
4. |
|
Shareholder Proposal on Annual Report Disclosing How Risks Related to Public Concern Over Drug Pricing Strategies are Incorporated into Incentive Compensation Plans |
|
Shareholder |
|
Against |
|
For |
|
5. |
|
Shareholder Proposal to Lower the Share Ownership Threshold to Call Special Shareholder Meetings |
|
Shareholder |
|
Against |
|
For |
|
CARDINAL HEALTH, INC.
Security |
14149Y108 |
Meeting Type |
Annual |
Ticker Symbol |
CAH |
Meeting Date |
08-Nov-2017 |
Record Date |
11-Sep-2017 |
|
|
Item |
|
Proposal |
|
Proposed |
|
Vote |
|
For/Against |
|
1A. |
|
ELECTION OF DIRECTOR: DAVID J. ANDERSON |
|
Management |
|
For |
|
For |
|
1B. |
|
ELECTION OF DIRECTOR: COLLEEN F. ARNOLD |
|
Management |
|
For |
|
For |
|
1C. |
|
ELECTION OF DIRECTOR: GEORGE S. BARRETT |
|
Management |
|
For |
|
For |
|
1D. |
|
ELECTION OF DIRECTOR: CARRIE S. COX |
|
Management |
|
For |
|
For |
|
1E. |
|
ELECTION OF DIRECTOR: CALVIN DARDEN |
|
Management |
|
For |
|
For |
|
1F. |
|
ELECTION OF DIRECTOR: BRUCE L. DOWNEY |
|
Management |
|
For |
|
For |
|
1G. |
|
ELECTION OF DIRECTOR: PATRICIA A. HEMINGWAY HALL |
|
Management |
|
For |
|
For |
|
1H. |
|
ELECTION OF DIRECTOR: CLAYTON M. JONES |
|
Management |
|
For |
|
For |
|
1I. |
|
ELECTION OF DIRECTOR: GREGORY B. KENNY |
|
Management |
|
For |
|
For |
|
1J. |
|
ELECTION OF DIRECTOR: NANCY KILLEFER |
|
Management |
|
For |
|
For |
|
1K. |
|
ELECTION OF DIRECTOR: DAVID P. KING |
|
Management |
|
For |
|
For |
|
2. |
|
PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING JUNE 30, 2018. |
|
Management |
|
For |
|
For |
|
3. |
|
PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. |
|
Management |
|
For |